Beauty
Health
Lifestyle
Medicine
Biowatch
Column
Kormedi.com TV
Notice
Newsletter subscription
Beauty
Health
Lifestyle
Medicine
Biowatch
Column
Kormedi.com TV
Notice
Languages
ENGLISH
English (US)
ASIAN
Монгол
日本語
Tiếng Việt
Bahasa Indonesia
中文 (简体, 中国大陆)
EUROPEAN
Русский
Español (España)
Français (France)
MIDDLE_EAST_AFRICA
العربية
Search results for "Daewoong Pharmaceutical"
Home
Seven-Day Fexuclue Regimen Cuts H. pylori Eradication Time in Half
Daewoong Pharmaceutical has raised the possibility of halving the treatment duration for Helicobacter pylori eradication using its gastroesophageal...
11/05/2026, 01:00 ET
Daewoong Pharmaceutical to Build Aseptic Manufacturing Facility for Semaglutide Microneedle Patch
Daewoong Pharmaceutical is accelerating efforts to secure Good Manufacturing Practice approval and establish an automated quality-control...
10/19/2026, 04:09 ET
Daewoong Pharmaceutical Enters Digital Therapeutics Market with Exclusive Deal for MCI Device 'Cogthera'
Daewoong Pharmaceutical announced on the 22nd that it has signed an exclusive domestic sales and commercialization...
09/30/2026, 01:32 ET
Daewoong Pharmaceutical Nears Completion of Phase 2 IPF Trial for Bersiporosin, Readout Set for H1 2027
Daewoong Pharmaceutical has completed patient enrollment for the global Phase 2 clinical trial of bersiporosin...
09/28/2026, 09:47 ET
Licensing Windfalls and Exports Split Performance Among Korea’s Top Drugmakers in Q2
South Korea’s five major legacy pharmaceutical companies largely extended their revenue growth in the second quarter,...
08/06/2026, 04:41 ET
Daewoong Pharmaceutical’s Nabota Enters Kuwait, Expanding Middle East Footprint to Seven Countries
Daewoong Pharmaceutical’s botulinum toxin product Nabota has entered Kuwait, expanding its Middle East footprint to...
07/31/2026, 21:02 ET
Daewoong Pharmaceutical Cuts Off Hospital Sales After Domestic Nabota Vials Surface in the U.S.
Daewoong Pharmaceutical announced on July 23 that it has severed supply transactions with a domestic medical...
07/26/2026, 08:54 ET
Daewoong Pharmaceutical’s Nabota Hits 1 Trillion Won in Cumulative Sales 12 Years Post-Launch
Daewoong Pharmaceutical announced on the 13th that its flagship botulinum toxin product, Nabota, surpassed 1 trillion...
07/14/2026, 08:19 ET
Daewoong’s Enblo Demonstrates Strong Potential to Reverse Fatty Liver in Diabetes Patients
Daewoong Pharmaceutical announced that its newly developed type 2 diabetes medication, Enblo (active ingredient:...
07/14/2026, 08:16 ET
Daewoong Pharmaceutical Secures 145.2 Billion Won MENA Export Deal for Diabetes Drug Enblo
Daewoong Pharmaceutical’s proprietary type 2 diabetes treatment, Enblo (active ingredient: enavogliflozin), is set to...
07/06/2026, 03:44 ET
1
2
3
Next